Germitec, a Bordeaux-based MedTech startup specialising in UV-C High-Level Disinfection solutions, has announced the successful closing of a €28.8 million financing round to accelerate its development in the U.S. and continue advancements in UV-C infection prevention technologies.
The round was led by European investment group Eurazeo through its Nov Santé Actions Non Cotées fund. Existing shareholders also participated in the round. Combined with prior funding from the European Investment Bank in 2023, this financing positions Germitec for sustained growth over the next two years, with profitability on the horizon.
“We are thrilled to welcome Eurazeo as a strategic investor and are equally grateful for the continued support from our existing shareholders,” said Vincent Gardès, Chief Executive Officer of Germitec. “This funding marks a significant milestone for Germitec as we expand our footprint in the U.S. and maintain our commitment to developing cutting-edge disinfection solutions that enhance patient safety and operational efficiency.”
Founded in 2005, Germitec’s flagship product line offers healthcare facilities fast, effective, and chemical-free solutions to prevent Healthcare-Associated Infections (HAIs) and improve the standard of care.
According to Germitec, the infectious risk is associated to the quality of hygiene practices surrounding the ultrasound procedure (hand hygiene, maintenance of the medical environment, ultrasound gel, and protective sheaths for probes), to the management, and the disinfection of the probes themselves.
As per figures on their website, 13% of vaginal probes used with sheaths test HPV positive after disinfection with wipes, 70% of HAIs can be prevented by implementing new infection control interventions, and that 15% of patients in low and mid-income countries will acquire at least one HAI during their hospital stay.
With global demand for infection prevention on the rise, Germitec’s solutions are well-positioned to address critical needs everywhere ultrasounds are performed: Fertility (IVF), gynaecology, cardiology, and Ear Nose and Throat (ENT) among other specialties. Thanks to the UV-C technology and its availability in 40 countries, 2.2 million patients are addressed across the world every year.
With an FDA De Novo granted in August 2024 and a market opportunity of 60k units in the U.S., Germitec is poised to quickly capture market share and “double its revenue every year.”
“One of Eurazeo’s key pillars is to invest in major public health challenges. We are therefore extremely proud to support Germitec with its UV-C High-Level Disinfection solutions for ultrasound probes, and its mission to revolutionise infection prevention,” said Arnaud Vincent, Managing Director – Healthcare, Eurazeo. “Germitec’s innovative UV-C technology aligns with our commitment to foster transformative healthcare solutions that improve patient outcomes and system sustainability.”
The proceeds from this financing round will be allocated to scaling U.S. operations, accelerating commercial adoption and investing in research and development to expand Germitec’s product portfolio. The company’s efforts aim to set new standards for disinfection efficiency and safety in the healthcare industry.
Read the orginal article: https://www.eu-startups.com/2025/02/germitec-raises-e28-8-million-for-uv-c-high-level-disinfection-in-ultrasounds/
